51 completed, 10 terminated, 4 unknown, 4 withdrawn. 76 Phase 2, 11 Phase 3, 10 Phase 1.
Follow Budesonide: new trials by email Literature Review of Budesonide trials Research Report on Budesonide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Little Lungs Study Calfactant, Budesonide - Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome | Phase 1 / Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 24 | 2027-02-01 | 2026-11-02 |
| Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol Fumarate, Placebo for CP006 Inhalation Powder - Asthma | Phase 2 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 150 | 2025-11-21 | 2026-09-08 |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo - Asthma | Phase 2 | Active not recruiting | Sanofi | 556 | 2024-11-07 | 2026-09-22 |
| Nasal Obstruction With Oxymetazoline and Corticosteroids Oxymetazoline Nasal Spray, Budesonide nasal spray - Nasal Obstruction | Phase 2 | Recruiting | Washington University School of Medicine | 80 | 2024-10-15 | 2025-09-11 |
| Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum budesonide, omeprazole (proton pump inhibitor) - Crohn Disease (CD) | Phase 2 / Phase 3 | Enrolling by invitation | Medical University of Warsaw | 114 | 2024-07-30 | 2024-12-06 |
| CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma Salbutamol, Fluticason either Beclometasone or Budesonide - Asthma | Phase 2 | Unknown | Università degli Studi di Ferrara | 80 | 2024-06-18 | 2024-07-03 |
| Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis Budesonide MMX®, Budesonide controlled ileal release (CR) capsules - Microscopic Colitis | Phase 2 | Active not recruiting | University of Calgary | 80 | 2024-03-21 | 2026-10-21 |
| Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant Budesonide EC, Placebo - Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Recruiting | University of Utah | 120 | 2023-05-03 | 2026-06-05 |
| Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19 Smell Retraining, Budesonide - Dysosmia, Anosmia | Phase 1 / Phase 2 | Terminated | Amanda Stapleton | 20 | 2021-09-30 | 2024-06-13 |
| Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics AQ001S 0.125 mg/ml, Budesonide 0.125 mg/ml inhalation suspension - Asthma | Phase 1 / Phase 2 | Completed | Aquilon Pharmaceuticals S.A. | 23 | 2021-07-23 | 2024-09-03 |
| Coronavirus Smell Therapy for Anosmia Recovery Budesonide, High-Concentration Essential Oil, Placebo - Anosmia | Phase 2 | Withdrawn | Washington University School of Medicine | 2021-06-01 | 2021-03-02 | |
| Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease Ibrutinib, ECG, PFT's - Chronic GVHD | Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2021-05-10 | 2026-01-23 |
| The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis Budesonide, Prednisone, Saline - Chronic Rhinosinusitis With Nasal Polyps | Phase 2 / Phase 3 | Completed | Kafrelsheikh University | 120 | 2021-05-01 | 2023-07-05 |
| STerOids in COVID-19 Study Budesonide dry powder inhaler - Coronavirus Infection | Phase 2 | Terminated | University of Oxford | 146 | 2020-07-16 | 2021-02-08 |
| Therapeutic Approaches to Malnutrition Enteropathy Colostrum high protein powder (Neovite), N-Acetyl Glucosamine (GInNAC), Teduglutide - Severe Acute Malnutrition | Phase 2 | Completed | Queen Mary University of London | 125 | 2020-05-04 | 2021-09-27 |
| Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome Budesonide, Placebo, Nebulizer - Acute Respiratory Distress Syndrome | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 2 | 2020-02-04 | 2022-07-13 |
| Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS) Nitric Oxide, Budesonide - Chronic Sinusitis | Phase 2 | Completed | Sanotize Research and Development corp. | 56 | 2019-10-27 | 2022-06-30 |
| Budesonide With Intratracheal Surfactants in Extremely Preterm Infants Budesonide in bovine lipid extract surfactant (BLES) - Bronchopulmonary Dysplasia, Respiratory Distress Syndrome in Premature Infant | Phase 1 / Phase 2 | Unknown | University of Manitoba | 30 | 2019-10-15 | 2019-07-17 |
| Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates Budesonide - Chronic Sinus Infection, Chronic Sinusitis | Phase 2 / Phase 3 | Withdrawn | Kaiser Permanente | 2019-08-13 | 2021-01-14 | |
| Inhaled Steroids for Acute Pharyngitis. Budesonide 0.25 MG/ML Inhalant Solution, Dexamethasone, Normal saline - Acute Pharyngitis | Phase 2 / Phase 3 | Completed | Oman Medical Speciality Board | 200 | 2019-06-01 | 2022-07-11 |
Showing 20 of 76. Sign in to see all of them.
Asthma (13) · Eosinophilic Esophagitis (6) · Pulmonary Disease, Chronic Obstructive (5) · Respiratory Distress Syndrome (4) · Bronchopulmonary Dysplasia (3) · Crohn Disease (3) · Rhinitis, Allergic, Seasonal (3) · Sinusitis (3) · Anosmia (2) · Bronchiolitis Obliterans (2) · COVID-19 (2) · Carcinoma, Non-Small-Cell Lung (2) · Colitis, Ulcerative (2) · Diarrhea (2) · Gastroesophageal Reflux (2)
AstraZeneca (7) · Dr. Falk Pharma GmbH (5) · Mayo Clinic (4) · Syntara (3) · Ligand Pharmaceuticals (2) · National Cancer Institute (NCI) (2) · Pari Pharma GmbH (2) · Sanofi (2) · Washington University School of Medicine (2) · ALK-Abelló A/S (1) · Activaero GmbH (1) · Allergan (1) · Amanda Stapleton (1) · Aquilon Pharmaceuticals S.A. (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (29) · Canada (13) · Germany (12) · United Kingdom (7) · Poland (6) · China (4) · France (4) · Italy (4) · Sweden (4) · Hungary (3) · Spain (3) · Australia (2) · Belgium (2) · Bulgaria (2) · Denmark (2)
Bertil Andersson (2) · Deepen Patel, MD (2) · Abdullah A Alangari, MBBS (1) · Adam M Zanation, MD (1) · Alan James, MBBS (1) · Alberto Papi, MD (1) · Alex Straumann, MD (1) · Alexander Gelbard, MD (1) · Alvaro J Coronado Munoz, MD (1) · Alvin Ing, MBBS (1) · Amanda L Stapleton, MD (1) · Amin Javer, MD (1) · Amy Foxx-Orenstein, D.O. (1) · Andrew Prendergast, PhD (1)
PMID 16164444, PMID 17148626, PMID 17296644, PMID 18958997, PMID 18972276, PMID 20457157, PMID 20600032, PMID 20719253, PMID 21163939, PMID 22111863, PMID 23076943, PMID 23810723, PMID 24092567, PMID 24384609, PMID 24907502, PMID 25473939, PMID 25792708, PMID 25835160, PMID 26460293, PMID 28194229, PMID 28240689, PMID 28418482, PMID 28931508, PMID 29702300, PMID 31352415, PMID 31634236, PMID 31727642, PMID 3197368, PMID 32006953, PMID 32205633, PMID 32301783, PMID 32464281, PMID 32484940, PMID 32681228, PMID 32738928, PMID 32962709, PMID 33028169, PMID 33388170, PMID 33844996, PMID 35397798, PMID 35666852, PMID 36702070, PMID 37192443, PMID 38632262, PMID 38746861, PMID 40272745, PMID 8022437, PMID 8628614
2015 (3), UL1RR024150 (2), 2008 (1), 2009 (1), 2016 (1), KL2TR003168 (1), P30CA012197 (1)